"This week the U.S. Food and Drug Administration approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (cannot be removed by surgery) or metastatic (late-stage)."...
SYLATRON is contraindicated in patients with:
- A history of anaphylaxis to peginterferon alfa-2b or interferon alfa-2b
- autoimmune hepatitis
- hepatic decompensation (Child-Pugh score > 6 [class B and C])
Last reviewed on RxList: 12/4/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Sylatron Information
Sylatron - User Reviews
Sylatron User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.